Skip to main navigation menu Skip to main content Skip to site footer


Vol 8 No 2 (2023): December

Serum Pentraxin-3 as a Potential Biomarker for Early Detection of Diabetic Nephropathy in Type 2 Diabetes Mellitus: A Cross-Sectional Study

(*) Corresponding Author
September 20, 2023


This cross-sectional study aimed to assess the utility of serum Pentraxin-3 (PTX-3) as a biomarker for the early identification of diabetic nephropathy (DN) in patients with Type 2 Diabetes Mellitus (T2DM). A total of 90 participants, including 30 with T2DM and nephropathy, 30 with T2DM but without nephropathy, and 30 controls, were enrolled. Serum PTX-3 levels were measured, and correlations with clinical parameters were analyzed. The results revealed a significant elevation in serum PTX-3 levels in DN patients with T2DM. PTX-3 exhibited positive correlations with age, disease duration, blood urea, and serum creatinine, indicating its potential relevance to DN development and renal function. Conversely, non-significant negative correlations were observed with BMI and estimated glomerular filtration rate (eGFR). These findings suggest that serum PTX-3 could serve as a valuable biomarker for the early detection of diabetic nephropathy in Type 2 Diabetes Mellitus, potentially aiding in timely intervention and improved patient care.

Highlights : 

  • Serum PTX-3 levels significantly elevated in Type 2 Diabetes patients with nephropathy, highlighting its potential as an early diagnostic biomarker.
  • Positive correlations observed between PTX-3, age, disease duration, blood urea, and serum creatinine, suggesting its relevance to DN development and renal function.
  • Serum PTX-3 holds promise for timely identification of diabetic nephropathy, facilitating improved patient care.

Keywords : Diabetic Nephropathy, Pentraxin-3, Type 2 Diabetes, Biomarker. Early Detection



  1. L. Gnudi and D.A. Long, "Diabetic Nephropathy: Methods and Protocols," New York, Springer, 2020, pp. 1-337.
  2. A.M. Egan and S.F. Dinneen, "What is diabetes?," Medicine, vol. 47, no. 1, pp. 1-4, 2019.
  3. M. Duvnjak and S.D. Lea, "Gastrointestinal complications of diabetes," Clinical Gastroenterology, 2018, pp. 3-47.
  4. E.J. Barrett et al., "Diabetic microvascular disease: An endocrine society scientific statement," J Clin Endocrinol Metab, vol. 102, no. 12, pp. 4343-4410, 2017.
  5. K. Papatheodorou et al., "Complications of diabetes 2017," J Diabetes Res, pp. 1-4, 2018.
  6. H.G.H. Guo et al., "Efficacy of tripterygium glycosides for diabetic nephropathy: A Meta-Analysis of Randomized Controlled Trials," 2021, pp. 1-12.
  7. Z. Ilyas, J.T. Chaiban, and A. Krikorian, "Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy," Rev Endocr Metab Disord, vol. 18, no. 1, pp. 21-28, 2017.
  8. J. Zhang, J. Liu, and X. Qin, "Advances in early biomarkers of diabetic nephropathy," Rev Assoc Med Bras, vol. 64, no. 1, pp. 85-92, 2018.
  9. R. Wang, J. Zhang, and W. Hu, "Association of serum pentraxin 3 concentrations with diabetic nephropathy," J Investig Med, vol. 64, no. 6, pp. 1124-1127, 2016.
  10. X. Chen et al., "Study on association of pentraxin 3 and diabetic nephropathy in a rat model," Journal of Diabetes Research, vol. 2018, pp. 1-10.
  11. A.A. Dawood et al., "Study of serum pentraxin 3 level in patients with diabetic nephropathy," Egypt J Intern Med, vol. 32, no. 3, pp. 1-9, 2020.
  12. S.A. Mezil, K.K. Ghudhaib, and A.A.D. Allawi, "Evaluation of serum pentraxin 3 level in Iraqi patients with diabetic nephropathy," Biochem Cell Arch, vol. 18, no. 2, pp. 2473-2477, 2018.
  13. Z. Feng Zhou et al., "Roles of pattern recognition receptors in diabetic nephropathy," J Zhejiang Univ Sci B, vol. 21, no. 3, pp. 192-203, 2020.
  14. M.J. Valente et al., "Long pentraxin 3 as a broader biomarker for multiple risk factors in end-stage renal disease: Association with all-cause mortality," Mediators Inflamm, vol. 2019, pp. 1-12.
  15. E. Aghadavod et al., "Comparison between biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy and type 2 diabetes mellitus," Iran J Kidney Dis, vol. 14, no. 1, pp. 31-35, 2020.
  16. E. Sharif and M. Alwakeel, "Neutrophil Gelatinase Associated Lipocalin: Is not an Early Marker Inductor for Diabetic Nephropathy in Qatari Population," vol. 22, no. 1, pp. 16345-16355, 2019.
  17. S.M. Al-Barshomy et al., "Serum and urinary pentraxin-3 levels in type 2 diabetes and its relation to diabetic nephropathy," Egypt J Intern Med, vol. 30, no. 4, pp. 182-190, 2018.
  18. M.I. Yilmaz et al., "Effect of renin-angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria," Clin J Am Soc Nephrol, vol. 4, no. 3, pp. 535-541, 2009.
  19. M.E. Suliman et al., "Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease," Clin J Am Soc Nephrol, vol. 3, no. 4, pp. 976-985, 2008.
  20. A.A. El Meligi et al., "Plasma long pentraxin 3 as a marker of endothelial dysfunction in early diabetic nephropathy," Egypt J Intern Med, vol. 25, no. 3, pp. 117, 2013.
  21. M. Tong et al., "Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality," Clin J Am Soc Nephrol, vol. 2, no. 5, pp. 889-897, 2007.
  22. R. Lee et al., "Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study," Int Urol Nephrol, vol. 49, no. 11, pp. 2027-2033, 2017.
  23. S. Uzun et al., "Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3," Renal Failure, vol. 38, no. 8, pp. 1193-1198, 2016.
  24. Y. Zhou et al., "Diabetic nephropathy can be treated with calcium dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function," Cell Physiol Biochem, vol. 51, no. 3, pp. 1119-1133, 2018.
  25. B. Li et al., "Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients," Int Urol Nephrol, vol. 52, no. 11, pp. 2145-2152, 2020.
  26. W.R.H. Al-Kraity, "Assessment of pentraxin 3 (PTX3) and sclerostin (SOST) levels in serum of patients with chronic kidney disease," Med Leg Update, vol. 21, no. 2, pp. 1274-1280, 2021.
  27. C. Salcini et al., "High plasma pentraxin 3 levels in diabetic polyneuropathy patients with nociceptive pain," Tohoku J Exp Med, vol. 239, no. 1, pp. 73-79, 2016.
  28. S.S. El Naidany, E. Zahran, and E.M.A. El Gayed, "Association of Pentraxin 3 rs2305619 (A/G) gene polymorphism and its serum level with the risk of nephropathy in type II diabetic patients," Gene Reports, vol. 20, pp. 100670-100678, 2020.
  29. F.M. El-senosy, M.E. Elwakeel, and R.E. Mohamed, "Study of Pentraxin-3 as an Early Marker of Diabetic Nephropathy in Type 2 Diabetes Mellitus," International Journal of Diabetes Research, vol. 7, no. 3, pp. 41-49, 2021.
  30. Y. XiaoYan et al., "Patients with type 2 diabetes pentraxin-3 correlation with urinary albumin," Progress in Modern Biomedicine, vol. 13, no. 16, pp. 3060-3062, 2013.
  31. H. Zhu et al., "Association of pentraxin 3 gene polymorphisms with susceptibility to diabetic nephropathy," Med Sci Monit, vol. 23, pp. 428-436, 2017.
  32. N. Abu Seman et al., "Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population," J Diabetes Res, vol. 2013, pp. 1-7.
  33. A. Witasp et al., "Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss," Obesity, vol. 22, no. 5, pp. 1373-1379, 2014.
  34. T. Miyazaki et al., "Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial," PLoS One, vol. 9, no. 4, pp. 1-8, 2014.
  35. N. Katakami et al., "Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients," Diabetes Res Clin Pract, vol. 99, no. 2, pp. 185-191, 2013.
  36. T.K. Outinen et al., "High pentraxin-3 plasma levels associate with thrombocytopenia in acute Puumala hantavirus-induced nephropathia epidemica," Eur J Clin Microbiol Infect Dis, vol. 31, no. 6, pp. 957-963, 2012.
  37. S. Ezzat, A. Selim, and M.A. El-Raouf Tawfik, "Long pentraxin PTX 3 and faecal calprotectin as a non-invasive biomarkers for ulcerative colitis," Archives of Clinical Gastroenterology, vol. 3, no. 1, pp. 11-16, 2017.
  38. R. Dubin et al., "Racial differences in the association of pentraxin-3 with kidney dysfunction," Nephrology Dialysis Transplantation, vol. 26, no. 6, pp. 1903-1908, 2011.


Download data is not yet available.